Incidence of Fever Following Endobronchial Ultrasound–Guided Transbronchial Needle Aspiration.
- Author:
Seo Yun KIM
1
;
Jin Woo LEE
;
Young Sik PARK
;
Chang Hoon LEE
;
Sang Min LEE
;
Jae Joon YIM
;
Young Whan KIM
;
Sung Koo HAN
;
Chul Gyu YOO
Author Information
- Publication Type:Original Article
- Keywords: Endoscopic Ultrasound-Guided Fine Needle Aspiration; Fever; Infection
- MeSH: Abscess; Body Temperature; Diabetes Mellitus; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Fever*; Humans; Incidence*; Logistic Models; Lymph Nodes; Lymphatic Diseases; Methods; Necrosis; Needles*; Retrospective Studies; Risk Factors; Seoul
- From:Tuberculosis and Respiratory Diseases 2017;80(1):45-51
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: Endobronchial ultrasound–guided transbronchial needle aspiration (EBUS-TBNA) is a minimally invasive diagnostic method for mediastinal and hilar lymphadenopathy. This study aimed to investigate the incidence of fever following EBUS-TBNA. METHODS: A total of 684 patients who underwent EBUS-TBNA from May 2010 to July 2012 at Seoul National University Hospital were retrospectively reviewed. The patients were evaluated for fever by a physician every 6–8 hours during the first 24 hours following EBUS-TBNA. Fever was defined as an increase in axillary body temperature over 37.8℃. RESULTS: Fever after EBUS-TBNA developed in 110 of 552 patients (20%). The median onset time and duration of fever was 7 hours (range, 0.5–32 hours) after EBUS-TBNA and 7 hours (range, 1–52 hours), respectively, and the median peak body temperature was 38.3℃ (range, 37.8–39.9℃). In most patients, fever subsided within 24 hours; however, six cases (1.1%) developed fever lasting longer than 24 hours. Infectious complications developed in three cases (0.54%) (pneumonia, 2; mediastinal abscess, 1), and all three patients had diabetes mellitus. The number or location of sampled lymph nodes and necrosis of lymph node were not associated with fever after EBUS-TBNA. Multiple logistic regression analysis did not reveal any risk factors for developing fever after EBUS-TBNA. CONCLUSION: Fever is relatively common after EBUS-TBNA, but is transient in most patients. However, clinicians should be aware of the possibility of infectious complications among patients with diabetes mellitus.
